The treatment has been around for decades, but has had a rocky history: It was widely prescribed from the 1960s through 1990s before usage came to an abrupt halt in 2002, when the Womens Health Initiative published findings suggesting that hormone therapy increased the risk of breast cancer, heart disease, stroke, and blood clots
At this point, we do not have a confirmation of the launch timeline and are working with the authorities concerned to finalise this." "If the price difference between the innovator product and the generic copycats is not significant, many will prefer to buy the innovator product," said Sheetal Sapale, vice-president, commercial, at industry tracker PharmaTrac
GLP-1 medications like Ozempic and Zepbound are highly effective for weight loss, but not all of that weight loss comes from fat
Between 2021 and 2023, commercial insurance carriers in Rhode Island spent over $120 million on GLP-1 medications alone
Nutrition Research, 1997
But one of the first questions providers ask is: When can I bill insurance for IV therapy? The answer depends on a combination of medical necessity, documentation, coding, and payer policy